The introduction of a standardized set of criteria to define invasive fungal infections has fulfilled a need. The criteria make comparisons between various clinical studies more easy and facilitate discussions of trial designs. However, application of the criteria in practice has indicated that some criteria for possible disease (in particular, antibiotic-resistant fever during neutropenia) are rather unspecific and allow the inclusion of patients who are unlikely to have an invasive fungal infection in trials. On the other hand, new diagnostic tools have been validated sufficiently to consolidate the effect of the criteria on the diagnosis of invasive fungal infections. Finally, it has become evident that changing medical practices with deleterious consequences for the innate immune system extend the population at risk for invasive fungal infections. This combination of factors has urged researchers to reconsider the continuing appropriateness of the current definitions.
The guidelines for defining the criteria used to diagnose invasive fungal infections in patients with cancer and in recipients of hematopoietic stem-cell transplants arose from a review by Ascioglu et al. [1] of published clinical trials of patients with hematologic malignancies and invasive fungal infections. That study showed that the level of overall agreement among studies of invasive fungal infection in this population was very low ( ). This result illustrates the discrepancy in the k p .253 medical literature in diagnosing invasive fungal infection and the necessity for the standardization of definitions.
Subsequently, guidelines for defining criteria to diagnose these invasive fungal infections were published by representatives of the European Organization for Research and Treatment of Cancer and the Mycoses Study Group (a forerunner of the current Bacterial and Mycoses Study Group) [2] . These guidelines, as established by a consensus panel, represented an effort to establish specific, reproducible criteria to allow stan-dardized entry of patients into clinical trials. These criteria were not recommended for use in evaluating patients in clinical practice, and they were to be applied to patients with the host risk factors of cancer and bone marrow transplantation, although they have been applied in clinical settings, as well as for patients with other host risk factors, such as solid-organ transplantation [3] . Clinical trials incorporating these criteria have now successfully been conducted, often with modifications that have allowed a more liberal entry of patients into clinical studies [4, 5] , although it has been noted in a clinical setting that significant numbers of patients with eventually proven fungal infection may well be excluded when these strict criteria are used [6] .
SPECIFIC CRITERIA
Since the introduction of these criteria for use in clinical trials, a growing body of evidence has shown that several individual criteria for the diagnosis of invasive fungal infection in the current guidelines can be identified as candidates for refinement, clarification, or revision (table 1) . Although these revisions may improve the utility of these guidelines, 2 key issues for criteria were recognized. The most important feature is that the criteria be readily reproducible and feasible to perform. In addition, it was also agreed that, for controversial criteria (i.e., detection of fungal DNA by PCR or detection of galactomannan from bronchoalveolar lavage fluid in the original guidelines), consensus on their value and reproducibility among the committee members had to be decisive for their inclusion. In addition, revision of the definitions should not render data collected on the basis of the original set useless and should allow a reasonable comparison of the results of the trials. Nevertheless, in a revised document, several specific features were identified as being in need of refinement, including removal of fever as a host factor, because it appears by consensus to be a clinical feature of infection, rather than a host factor of risk of infection. In addition, specification of immunosuppression (such as timing of neutropenia and steroid dosage or duration of use) would further refine the criteria. Elimination of nonspecific criteria, such as persistent fever alone, pleural effusions, and nonspecific retinal signs, would also be useful to reduce the number of patients not likely to have invasive mycoses, which by consensus was suggested to be a goal of revised criteria. The need for expanding and clarifying the criteria to include other groups of patients, such as recipients of solid-organ transplants, was recognized, as was the interest in expanding the criteria to assess the growing spectrum of unusual molds in immunosuppressed patients.
The category of proven infections was recognized as reliable and reproducible. For patients with probable infection, it was also agreed that current criteria do not give appropriate weight to criteria in this category. For example, positive microbiological criteria (such as a respiratory sample or bronchoalveolar lavage fluid sample positive for Aspergillus species) should be given more weight than tests in those patients identified by less strict criteria (such as a positive antigen test or even a "halo sign" on CT for a high-risk patient) for whom microbiological criteria are not identified. For those patients entered into trials of invasive pulmonary aspergillosis, it was agreed that a halo sign on CT plus a host factor, such as allogeneic bone marrow transplantation or persistent neutropenia, put the patient at sufficient risk for invasive aspergillosis to allow an upgrade from their present categorization as having possible aspergillosis for the purpose of differentiating them from patients with lesstypical pulmonary infiltrates. This conclusion had been borne out in the global voriconazole trial and by extensive clinical experience [7, 8] . However, it is important that patients with mycological evidence of fungal disease remain the backbone of the populations intended for epidemiological surveys and trials of therapy, as was done in the global trial of voriconazole to treat aspergillosis [4] .
The role of surrogate markers in diagnosing invasive fungal infections remains a subject of debate. Clinical validation data support the use of detection of galactomannan, whereas the use of PCR does not meet the criteria of being standardized and reproducible. Until that level of confidence is reached, it was agreed that PCR analysis should not be used in diagnostic criteria for clinical trial purposes.
FUTURE STUDIES
The aim of these guidelines was agreed to be the inclusion of as many patients with infection as possible and the exclusion of patients without infection. The current criteria include too many patients classified as having possible disease who do not actually have infection but admit only a portion of patients with eventually proven invasive disease. The challenge of revised guidelines will be to include more patients with proven infection while not including those patients unlikely to have an invasive mycosis. Once drugs or strategies have been assessed in robust clinical trials with an adequate number of patients with unequivocal invasive fungal infections, they can be used with sufficient confidence in daily clinical practice when clinical suspicion of an invasive fungus is often very high, but definite proof is unobtainable.
Validation remains a critical component. Subira et al. [6] showed that 64% of their patients with proven invasive aspergillosis at autopsy did not meet criteria for the diagnosis before their death. Future trials should incorporate validation of these criteria in order to critically evaluate their predictive value in the diagnosis of invasive fungal infections.
What do we conclude from recent studies regarding the use of the Aspergillus Platelia galactomannan test in the diagnosis of invasive aspergillosis? Should a galactomannan index of 0.5 be allowed for study entry or an end point for failure in a prophylaxis trial? It was agreed that compelling evidence emerging about the utility of the Platelia assay to detect galactomannan supports this test as valid diagnostic tool [9, 10] . Nevertheless, several areas of concern were identified. Receiveroperator characteristic curves showed a significant increase in sensitivity with the reduction of the cutoff between a positive and negative result from a galactomannan index of 1.5 to 0.5.
The reduced threshold appears to be a valid cutoff [10] . Nevertheless, the specificity per patient (rather than per test) decreased to ∼70% in the study by Marr et al. [10] . Thus, it was agreed that a positive result in the setting of compatible clinical disease should allow study entry, as defined in the current guidelines [2] . However, because of the lower per-patient specificity of this revised threshold, it was recognized that, as a sole criterion it should not be used as a study end point to define failure, particularly in trials of antifungal prophylaxis. Because results of this assay are suggested to be interpreted in the setting of other criteria for invasive aspergillosis, there was concern by some panel members that the value added of this test could not yet be determined, and additional studies on validation were suggested.
Should PCR be used for study entry on the basis of recent studies? Although major advances in this important area of fungal diagnosis have recently been reported [11] [12] [13] [14] , the consensus regarding the use of these tests in current guidelines was that they did not meet the important criteria of validation, reproducibility, or standardization. Nevertheless, the panel recognized the importance of these tools and suggested that future guidelines allow their incorporation when these criteria are met.
Do surrogate markers for the diagnosis of invasive fungal infections affect regulatory approval of antifungal agents?
The use of surrogate markers for approval of antifungal agents is controlled by the Code of Federal Regulations, which governs regulatory approval in the United States. Validation of surrogate markers for use as end points in clinical trials is critical and can be accomplished in some trials. This has been done in trials of HIV-infected patients by long-term follow-up, which has validated certain surrogate markers as predictive of clinical end points. In trials of invasive mycoses, this is more difficult, because long-term follow-up to validate an early surrogate marker is not usually practical.
The aim of valid surrogate markers is not only that they are precise (i.e., highly reproducible) but also that they are accurate and convey useful information about the disease under study. At the current time, surrogate markers in the diagnosis of invasive aspergillosis and serious Candida infection have limited usefulness, with validation still needed, although the promise for galactomannan detection is noted. However, the panel concluded that surrogate markers for the diagnosis of invasive mycoses offer significant promise in establishing an early diagnosis and suggested that this area continue to be the focus of intensive basic and clinical investigation.
